[ad_1]
A Canadian pharmaceutical company is about to manufacture a vaccine for the coronavirus, which differs from vaccines produced so far.
A Canadian pharmaceutical company is close to entering the third phase of clinical trials to develop a coronavirus vaccine, which differs from vaccines produced so far.
The secret is not in the vaccine itself, but in the method used by the company “Medicago” from the Canadian province of Quebec, which would produce 10 million doses per month, according to a report on the website “Defense One”.
The company began the accreditation of 30,000 people from ten different countries in Europe, North America and South America, in order to obtain the Corona vaccine, as part of the third clinical trials of the vaccine.
In contrast to traditional vaccine production processes, in which live virus is injected into a chicken egg, to initiate virus reproduction, Medicago took a different approach.
The company inserted a genetic sequence of the virus into a soil bacterium, which was detected by a plant that resembles a tobacco plant, according to the Defense One report.
The cultures used in experiments belonging to this type of plants carry a protein that can be used in the production of an anti-coronavirus vaccine and can be modified to resist new strains of the virus.
The American company “Darpa” for military industries had supported research on this technology, called “Blue Angel” in 2009, and aims to develop technology to produce vaccines in general at a faster rate.
The company “Medicago” is currently working with the British pharmaceutical company “GlaxoSmithKline”, which provides the basic substance of the components of the vaccine, which gives the body immunity against the virus.
“If we succeed and then take the fast track to get US permission, we will have the capacity to produce more than 80 million doses in the next 12 months,” said Brian Ward, professor of medicine and microbiology at the University. McGill and Medicago’s chief medical officer.
“So (we will produce) 160 million next year,” added the doctor. Ward believes the company should be able to produce millions of doses by August.
Ward explained that once scientists obtain the genetic information about the virus they want to develop a vaccine against, the new (vegetarian) method can produce a vaccine within five to six weeks, rather than months as is the case with traditional methods.
The Defense One report concluded by saying that the third phase of clinical trials will be the deciding factor in determining the effectiveness of the vaccine against the virus.
And the results during the first and second stages proved highly effective in neutralizing viruses, like other vaccines, or even more, Ward said.
[ad_2]
